Concurrent centrifugation plasmapheresis and continuous venovenous hemodiafiltration.
Continuous venovenous hemofiltration/hemodiafiltration (CVVH/D) is commonly used to provide renal replacement therapy for critically ill patients who are hemodynamically unstable. Occasionally, the addition of plasmapheresis therapy is necessary for some conditions, including immune-mediated acute renal failure, sepsis, fulminant hepatic failure, and thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Most tertiary care facilities provide centrifugation plasmapheresis instead of membrane plasmapheresis, because of the requirement for both therapeutic plasma exchange and pheresis of cellular blood products. We report a new technique where centrifugation plasmapheresis and CVVHD (P-CVVHD) are combined and used concurrently. Blood from the patient was concurrently filtered utilizing a Hospal BSM 22 machine with a Multiflow 60 hemofilter and a Cobe Spectra continuous cell separator in a parallel configuration. P-CVVHD is technically possible and can be used for long periods of time with limited risks. There may be advantages to P-CVVHD compared with discontinuous combined CVVH/D and plasmapheresis therapy.
Yorgin
P D
PD
Department of Pediatrics, University of Arizona, Steele Memorial Children's Research Center, Tucson 85724, USA. pyorgin@peds.arizona.edu
Eklund
D K
DK
al-Uzri
A
A
Whitesell
L
L
Theodorou
A A
AA
D000293:Adolescent; D019343:Citric Acid / Q000097:blood; D005260:Female; D017583:Hemodiafiltration / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D007677:Kidney Function Tests; D015456:Leukemia, Biphenotypic, Acute / Q000150:complications; D010953:Plasma Volume; D010956:Plasmapheresis / Q000295:instrumentation / Q000379:methods*; D014883:Water-Electrolyte Imbalance / Q000150:complications / Q000628:therapy
D019343:Citric Acid